Clinical stage pharmaceutical development Company Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) revealed the pricing of its marketed public offering on Friday. The Company will offer a minimum of 22 million units and a maximum of 45 million units at $0.11 per Unit for minimum gross proceeds of $2.5 million and maximum gross proceeds of $5 million.
For more on this news, click here.
Recently, AGN reported that its lead drugfor inflammatory bowel disease (IBD) is Emoxypine (NP-178), a small molecule delivered orally. It is one of the top-five selling drugs on the essential medicines list in Russia for the treatment of several neurological conditions.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.